Do you want to read an article? Please log in or register.
Prior Glucose-Lowering Medication Use and 30-Day Outcomes Among 64,892 Veterans With Diabetes and COVID-19
COVID-19
COMMENTED
Related content
COVID-19
Glycaemic control during the lockdown for COVID-19 in adults with type 1 diabetes: A meta-analysis of observational studies
Diabetes Res Clin Pract
Garofolo M, Aragona M, Rodia C, Falcetta P, Bertolotto A, Campi F, Del Prato S, Penno G
doi: 10.1016/j.diabres.2021.109066
COVID-19
Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities
Clin Res Cardiol
Rieder M, Gauchel N, Kaier K, Jakob C, Borgmann S, Classen AY, Schneider J, Eberwein L, Lablans M, Rüthrich M, Dolff S, Wille K, Haselberger M, Heuzeroth H, Bode C, von Zur Mühlen C, Rieg S, Duerschmied D
doi: 10.1007/s00392-021-01939-3
COVID-19Cardiovascular
COVID-19 et maladies cardiovasculaires : une association à double sens
healthbook TIMES
RECOMMENDED
COVID-19
COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
Agrawal U, Katikireddi SV, McCowan C, Mulholland RH, Azcoaga-Lorenzo A, Amele S, Fagbamigbe AF, Vasileiou E, Grange Z, Shi T, Kerr S, Moore E, Murray JLK, Shah SA, Ritchie L, O'Reilly D, Stock SJ, Beggs J, Chuter A, Torabi F, Akbari A, Bedston S, McMenamin J, Wood R, Tang RSM, de Lusignan S, Hobbs FDR, Woolhouse M, Simpson CR, Robertson C, Sheikh A
doi: 10.1016/S2213-2600(21)00380-5
COVID-19
Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19
Circ Heart Fail
Goyal P, Reshetnyak E, Khan S, Musse M, Navi BB, Kim J, Allen LA, Banerjee S, Elkind MSV, Shah SJ, Yancy C, Michos ED, Devereux RB, Okin PM, Weinsaft JW, Safford MM
doi: 10.1161/CIRCHEARTFAILURE.121.008354
COVID-19
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial
JAMA Intern Med
Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI, HEP-COVID Investigators.
doi: 10.1001/jamainternmed.2021.6203
RECOMMENDED
COVID-19
Severe COVID-19 among patients with asthma and COPD: a report from the Swedish National Airway Register
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Ther Adv Respir Dis
Karlsson Sundbaum J, Vanfleteren LEGW, Konradsen JR, Nyberg F, Ekberg-Jansson A, Stridsman C
doi: 10.1177/17534666211049738
COVID-19
Pandémie de COVID-19 : un défi et une chance pour la santé mentale de la population
healthbook TIMES
COVID-19
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19
Ann Rheum Dis
Alunno A, Najm A, Machado PM, Bertheussen H, Burmester GR, Carubbi F, De Marco G, Giacomelli R, Hermine O, Isaacs JD, Koné-Paut I, Magro-Checa C, McInnes IB, Meroni PL, Quartuccio L, Ramanan AV, Ramos-Casals M, Rodríguez Carrio J, Schulze-Koops H, Stamm TA, Tas SW, Terrier B, McGonagle DG, Mariette X
doi: 10.1136/annrheumdis-2021-221366